$MDAI
Spectral AI, Inc. Stock $mdai

$mdai Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024027863 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$6.326M	$5.287M	$18.06M
YoY Change
Cost Of Revenue	$3.381M	$2.851M	$10.18M
YoY Change	16.71%		-29.82%
Gross Profit	$2.945M	$2.436M	$7.880M
YoY Change	35.03%		-27.29%
Gross Profit Margin	46.55%	46.08%	43.64%
Selling, General & Admin	$5.088M	$5.365M	$20.86M
YoY Change	864.77%	1687.62%	1567.73%
% of Gross Profit	172.77%	220.24%	264.77%
Research & Development	$4.300M		$15.10M
YoY Change	7.5%		-8.48%
% of Gross Profit	146.01%		191.62%
Depreciation & Amortization	$3.000K	$2.000K	$9.000K
YoY Change	50.0%		-18.18%
% of Gross Profit	0.1%	0.08%	0.11%
Operating Expenses	$4.300M	$5.365M	$20.86M
YoY Change	715.35%	1687.62%	1567.73%
Operating Profit	-$2.143M	-$2.929M	-$12.98M
YoY Change	306.35%		937.86%
Interest Expense	-$2.000K	$31.00K	$148.0K
YoY Change	-99.73%	-98.45%	-98.85%
% of Operating Profit
Other Income/Expense, Net	-$1.040M	-$669.0K	-$8.007M
YoY Change	31.91%
Pretax Income	-$3.183M	-$3.567M	-$20.84M
YoY Change	149.65%	-309.44%	-278.86%
Income Tax	$22.00K	-$21.00K	$11.00K
% Of Pretax Income
Net Earnings	-$3.205M	-$3.546M	-$20.85M
YoY Change	149.98%	-364.51%	-288.91%
Net Earnings / Revenue	-50.66%	-67.07%	-115.5%
Basic Earnings Per Share	-$0.19		-$1.48
Diluted Earnings Per Share	-$0.19	-$0.47	-$1.48
COMMON SHARES
Basic Shares Outstanding	17.47M shares	16.25M shares	14.09M shares
Diluted Shares Outstanding	16.56M shares		14.09M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.16M	$4.790M	$4.790M
YoY Change	1774.54%	510.16%	510.16%
Cash & Equivalents	$10.16M	$4.790M	$4.790M
Short-Term Investments
Other Short-Term Assets	$1.090M	$2.536M	$2.536M
YoY Change	434.76%	1551.26%	1551.26%
Inventory	$228.0K	$230.0K	$230.0K
Prepaid Expenses	$1.581M	$1.452M
Receivables	$1.828M	$2.346M	$2.346M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.88M	$9.902M	$9.902M
YoY Change	1896.05%	954.96%	954.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.000K	$790.0K	$790.0K
YoY Change		3661.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$599.0K	$790.0K	$790.0K
YoY Change	-87.16%	-82.92%	-82.92%
TOTAL ASSETS
Total Short-Term Assets	$14.88M	$9.902M	$9.902M
Total Long-Term Assets	$599.0K	$790.0K	$790.0K
Total Assets	$15.48M	$10.69M	$10.69M
YoY Change	186.06%	92.14%	92.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.306M	$2.683M	$2.683M
YoY Change		-2.75%
Accrued Expenses	$3.818M	$3.483M	$3.483M
YoY Change	3.56%	3.9%	3.9%
Deferred Revenue		$2.311M
YoY Change
Short-Term Debt	$5.752M	$436.0K	$436.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.51M	$12.40M	$12.40M
YoY Change	341.61%	242.22%	242.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.51M	$12.40M	$12.40M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$17.51M	$12.40M	$12.40M
YoY Change	25.05%	-3.67%	-3.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.00M	-$32.79M
YoY Change	168.54%	171.05%
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.028M	-$1.709M	-$1.709M
YoY Change
Total Liabilities & Shareholders Equity	$15.48M	$10.69M	$10.69M
YoY Change	186.06%	92.14%	92.14%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.205M	-$3.546M	-$20.85M
YoY Change	149.98%	-364.51%	-288.91%
Depreciation, Depletion And Amortization	$3.000K	$2.000K	$9.000K
YoY Change	50.0%		-18.18%
Cash From Operating Activities	-$2.680M	-$2.375M	-$13.24M
YoY Change	1001.99%	463.61%	1199.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.667M
YoY Change			-98.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.049M	-195.0K	3.844M
YoY Change	-7839.42%	-99.92%	-101.53%
NET CHANGE
Cash From Operating Activities	-$2.680M	-2.375M	-13.24M
Cash From Investing Activities
Cash From Financing Activities	$8.049M	-195.0K	3.844M
Net Change In Cash	$5.367M	-2.570M	-9.396M
YoY Change	-2306.85%	-1061.83%	-60307.61%
FREE CASH FLOW
Cash From Operating Activities	-$2.680M	-$2.375M	-$13.24M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40058
CY2023	dei	Entity Registrant Name EntityRegistrantName	SPECTRAL AI, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3987148
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2515 McKinney Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1000
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75201
CY2023	dei	City Area Code CityAreaCode	(972)
CY2023	dei	Local Phone Number LocalPhoneNumber	499-4934
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	81000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17466871	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4790000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14174000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2346000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2294000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	230000	usd
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	618000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	283000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1452000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	331000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	801000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	270000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9902000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	17687000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	778000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1008000	usd
CY2023Q4	us-gaap	Assets Assets	10692000	usd
CY2022Q4	us-gaap	Assets Assets	18716000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2683000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2759000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4300000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2631000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2311000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	853000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	680000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	436000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	175000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1818000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	129000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12401000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6374000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	346000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12401000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6720000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16294935	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16294935	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13170148	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13170148	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31065000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23929000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32788000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11934000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1709000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11996000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10692000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18716000	usd
CY2023	us-gaap	Revenues Revenues	18056000	usd
CY2022	us-gaap	Revenues Revenues	25368000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	10176000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	14531000	usd
CY2023	us-gaap	Gross Profit GrossProfit	7880000	usd
CY2022	us-gaap	Gross Profit GrossProfit	10837000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20864000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13484000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20864000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	13484000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-12984000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2647000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	172000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	21000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-335000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-57000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-24000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-237000	usd
CY2023	mdai	Transaction Costs Incurred In Connection With Warrant Liabilities TransactionCostsIncurredInConnectionWithWarrantLiabilities	8342000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7859000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-159000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20843000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2806000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	106000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20854000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2912000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14087586	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13136965	shares
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	12000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20842000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2912000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13753000	usd
CY2022	mdai	Balance After Effect Of Business Combination BalanceAfterEffectOfBusinessCombination	13753000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1155000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2912000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11996000	usd
CY2023	mdai	Stock Issued During Period Value Issuance Of Common Stock Upon Business Combination StockIssuedDuringPeriodValueIssuanceOfCommonStockUponBusinessCombination	-2374000	usd
CY2023	mdai	Stock Issued During Period Value Issuance Of Common Stock To Settle Accounts Payable StockIssuedDuringPeriodValueIssuanceOfCommonStockToSettleAccountsPayable	150000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4350000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3351000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	101000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1243000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	316000	usd
CY2023	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	12000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20854000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1709000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20854000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2912000	usd
CY2023	us-gaap	Depreciation Depreciation	9000	usd
CY2022	us-gaap	Depreciation Depreciation	11000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1243000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1155000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-713000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-557000	usd
CY2023	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	4350000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-335000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-57000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	859000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	230000	usd
CY2023	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-618000	usd
CY2022	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	547000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	377000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-615000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	404000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-40000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-935000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1345000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1359000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	51000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2311000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-656000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-561000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13240000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1162000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3351000	usd
CY2023	mdai	Cash Received In Business Combination CashReceivedInBusinessCombination	-660000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	483000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	785000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	316000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3844000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-785000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9384000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1947000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14174000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16121000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4790000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14174000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	29000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	23000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	114000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	53000	usd
CY2022	mdai	Recognition Of Rightofuse Assets And Related Lease Liabilitie Upon Adoption Of Asc842 RecognitionOfRightofuseAssetsAndRelatedLeaseLiabilitieUponAdoptionOfASC842	610000	usd
CY2023	mdai	Recognition Of Rightofuse Assets And Related Lease Liabilities Upon Lease Amendment RecognitionOfRightofuseAssetsAndRelatedLeaseLiabilitiesUponLeaseAmendment	483000	usd
CY2022	mdai	Recognition Of Rightofuse Assets And Related Lease Liabilities Upon Lease Amendment RecognitionOfRightofuseAssetsAndRelatedLeaseLiabilitiesUponLeaseAmendment	955000	usd
CY2023	mdai	Issuance Of Common Stock For Net Liabilities Upon Business Combination IssuanceOfCommonStockForNetLiabilitiesUponBusinessCombination	3034000	usd
CY2023	mdai	Prepaid Asset Acquired Net Of Cancellation For Debt And Accounts Payable PrepaidAssetAcquiredNetOfCancellationForDebtAndAccountsPayable	744000	usd
CY2022	mdai	Prepaid Asset Acquired Net Of Cancellation For Debt And Accounts Payable PrepaidAssetAcquiredNetOfCancellationForDebtAndAccountsPayable	376000	usd
CY2023	mdai	Issuance Of Common Stock To Settle Accounts Payable IssuanceOfCommonStockToSettleAccountsPayable	150000	usd
CY2023	mdai	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	182000	usd
CY2023	mdai	Issuance Of Common Stock To Settle Deferred Offering Costs IssuanceOfCommonStockToSettleDeferredOfferingCosts	101000	usd
CY2023	mdai	Common Stock Exchange Ratio Price CommonStockExchangeRatioPrice	10.31
CY2023Q3	mdai	Contract Value ContractValue	150000000	usd
CY2023Q4	mdai	Contract Inital Award Value ContractInitalAwardValue	54900000	usd
CY2023Q2	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	4000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14200000	usd
CY2023Q4	mdai	Aggregate Gross Purchase Price AggregateGrossPurchasePrice	10000000	usd
CY2023	mdai	Percentage Of Shares Of Common Stock Issued PercentageOfSharesOfCommonStockIssued	0.1999	pure
CY2023Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	150000000	usd
CY2023	mdai	Aggregated Funding Options AggregatedFundingOptions	251000000	usd
CY2023	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	106500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, warrant liabilities, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets and income tax valuation allowances. Actual results could differ from these estimates.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">Financial instruments which potentially subject the Company to credit risk consist principally of cash and accounts receivable. Primarily all cash is held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2023 and December 31, 2022, receivables were concentrated from one customer (which is a US. government agency) representing 92% and 96% of total net receivables, respectively. No allowance for doubtful accounts were recorded as of December 31, 2023 and December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">One customer (which is a U.S. government agency) accounted for 95% for the year ended December 31, 2023 and 98% for the year ended December 31, 2022 of the recognized research and development revenue.</span></p>
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.5
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15100000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16500000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	10200000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	14500000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	5300000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	600000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	660000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	127000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	860000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	277000	usd
CY2023Q4	mdai	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiabilities	-2024000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	-2374000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets	660000	usd
CY2023Q4	mdai	Noncash Net Assets Assumed In Exchange For Common Stock NoncashNetAssetsAssumedInExchangeForCommonStock	-3034000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	800000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	500000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1818000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	129000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	186000	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-57000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	129000	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-82000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	47000	usd
CY2023	us-gaap	Revenues Revenues	18056000	usd
CY2022	us-gaap	Revenues Revenues	25368000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1910000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1135000	usd
CY2023Q4	mdai	Accrued Operating Expenses AccruedOperatingExpenses	1563000	usd
CY2022Q4	mdai	Accrued Operating Expenses AccruedOperatingExpenses	736000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	720000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	650000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	107000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	110000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4300000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2631000	usd
CY2023	mdai	Principal Repayments Insurance Note PrincipalRepaymentsInsuranceNote	483000	usd
CY2022	mdai	Principal Repayments Insurance Note PrincipalRepaymentsInsuranceNote	361000	usd
CY2023	mdai	Insurance Note Outstanding Balance InsuranceNoteOutstandingBalance	436000	usd
CY2022	mdai	Insurance Note Outstanding Balance InsuranceNoteOutstandingBalance	175000	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	38000000	usd
CY2020Q2	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	700000	usd
CY2022Q2	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.01	pure
CY2022	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	400000	usd
CY2023Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P12M
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	744000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	594000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	483000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1565000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	802000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	590000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	357000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	126000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1159000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	716000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	110000	usd
CY2023	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1269000	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	716000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	894000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	894000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	41000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	853000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6636000	usd
CY2023Q4	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	3.2
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	58197	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.65
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	58197	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.65
CY2023	mdai	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Fair Value Of Common Stock SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock	4.57
CY2022	mdai	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Fair Value Of Common Stock SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock	4.52
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.72	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.68	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3503790	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.06
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6831000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	253250	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.57
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	31846	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	20368	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.23
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	126247	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.13
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578579	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.2
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8041000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2898508	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.76
CY2022Q4	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	2.79
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	200000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.038	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.028	pure
CY2023	mdai	Effective Income Tax Rate Reconciliation Tax Permanent Items EffectiveIncomeTaxRateReconciliationTaxPermanentItems	-0.0927	pure
CY2022	mdai	Effective Income Tax Rate Reconciliation Tax Permanent Items EffectiveIncomeTaxRateReconciliationTaxPermanentItems	-0.073	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.025	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	0.0008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1182	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.122	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.038	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0006	pure
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-5000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	101000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	106000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	106000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2403000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	429000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	717000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	420000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	437000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	278000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	262000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	179000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	216000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	44000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	10000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	438000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	269000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4496000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1606000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1388000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	163000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	218000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	163000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	212000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-6000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	163000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	218000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	300000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P5Y
CY2023	us-gaap	Amortization Period Of Deferred Gain Loss On Discontinuation Of Foreign Currency Fair Value Hedge1 AmortizationPeriodOfDeferredGainLossOnDiscontinuationOfForeignCurrencyFairValueHedge1	P15Y
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	3000000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1700000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	11000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3100000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12144087	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4547066	shares
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent		usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2022	mdai	Transaction Costs Incurred In Connection With Warrant Liabilities TransactionCostsIncurredInConnectionWithWarrantLiabilities		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13136965	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14087586	shares
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax		usd
CY2022Q4	mdai	Temporary Equity Retroactive Application Of Recapitalizations TemporaryEquityRetroactiveApplicationOfRecapitalizations		usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	mdai	Cash Received In Business Combination CashReceivedInBusinessCombination		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	mdai	Recognition Of Rightofuse Assets And Related Lease Liabilitie Upon Adoption Of Asc842 RecognitionOfRightofuseAssetsAndRelatedLeaseLiabilitieUponAdoptionOfASC842		usd
CY2022	mdai	Issuance Of Common Stock For Net Liabilities Upon Business Combination IssuanceOfCommonStockForNetLiabilitiesUponBusinessCombination		usd
CY2022	mdai	Issuance Of Common Stock To Settle Accounts Payable IssuanceOfCommonStockToSettleAccountsPayable		usd
CY2022	mdai	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses		usd
CY2022	mdai	Issuance Of Common Stock To Settle Deferred Offering Costs IssuanceOfCommonStockToSettleDeferredOfferingCosts		usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther		pure
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001833498

Files In Submission

Name	View Source	Status
0001213900-24-027863-index-headers.html	Edgar Link	pending
0001213900-24-027863-index.html	Edgar Link	pending
0001213900-24-027863.txt	Edgar Link	pending
0001213900-24-027863-xbrl.zip	Edgar Link	pending
ea0202419-10k_spectral.htm	Edgar Link	pending
ea0202419-10k_spectral_htm.xml	Edgar Link	completed
ea020241901ex10-12_spectral.htm	Edgar Link	pending
ea020241901ex14_spectral.htm	Edgar Link	pending
ea020241901ex19_spectral.htm	Edgar Link	pending
ea020241901ex21_spectral.htm	Edgar Link	pending
ea020241901ex23-1_spectral.htm	Edgar Link	pending
ea020241901ex31-1_spectral.htm	Edgar Link	pending
ea020241901ex31-2_spectral.htm	Edgar Link	pending
ea020241901ex32-1_spectral.htm	Edgar Link	pending
ea020241901ex97_spectral.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex23-1_002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003a.jpg	Edgar Link	pending
image_003b.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
mdai-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
mdai-20231231_cal.xml	Edgar Link	unprocessable
mdai-20231231_def.xml	Edgar Link	unprocessable
mdai-20231231_lab.xml	Edgar Link	unprocessable
mdai-20231231_pre.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDAI
Spectral AI, Inc. Stock $mdai

2024 Q1 Form 10-K Financial Statement

#000121390024027863 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDAI Spectral AI, Inc. Stock $mdai

2024 Q1 Form 10-K Financial Statement

#000121390024027863 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDAI
Spectral AI, Inc. Stock $mdai